Charlotte’s Milestone Pharmaceuticals advancing heart drug
Joseph Oliveto, Milestone’s president and chief executive officer, said he expected the FDA to render a decision on the drug in about a year from now.
Read MoreDrugs
Drugs like Ozempic and Wegovy could strengthen the US economy, Goldman Sachs predicts
Goldman Sachs argues that since poor health unambiguously weighs on the economy, improving health outcomes due to GLP-1s could lower costs and boost productivity, shoring up economic output.
Read More
Angioedema drug’s upside puts BioCryst on path to profits in 2026
Sales of Orladeyo have jumped to $326 million last year from $133,000 in 2020. The company expects revenue from the drug of as much as $400 million this year.
Read More
Wireless drug patch shows promise as chronic disease treatment delivery system
Research suggests that a wearable patch featuring electrically triggered microneedles for on-demand drug delivery could be the next frontier in treatment of neurodegenerative disorders and neurological injuries.
Read More
Many drug prices are going up in ’23 – brace yourselves
Prices on some 350 drugs are headed up, says a new report from Reuters and FiercePharma. And many of those are big names.
Read More
‘Drug checking’ programs lead to unexpected benefits, NCSU study finds
A recent study has found that so-called “drug checking” programs have unexpected benefits, allowing public health programs to reach and work with people who use drugs who would otherwise not access services such as HIV testing.
Read MoreInsulin pricing under review as Congress begins hearings on drug prices
A senior Republican lawmaker said Tuesday he plans to investigate price spikes in the cost of insulin for people with diabetes as Congress opened hearings on the high cost of prescription drugs.
Read More
